A Phase 2 interventional study of 100 mg AMG 162 and 60 mg AMG 162 in Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2013-06-20.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.
Among the 64 studies testing denosumab in Osteoporosis, this one is the 20th largest by enrollment, is one of 5 that started in 2006, is one of 14 in phase 2, and was the 5th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 50–85 · Women only
Aarhus University Hospital · Sites in Denmark
Ages 40+ · Women only
Chrissy Kistler · Sites in United States
Ages 65+
Wuhan Union Hospital, China · Sites in China
Ages 40+
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: Up to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 25 · Phase 4 19
First in 2002; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 212 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 90 across the 64 interventional studies. Of the 45 that completed or were terminated, 32 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 64 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
34 studies in Osteoporosis by Amgen: none open now, 2 under way, none of them phase 3. Of 32 finished, 31 (97%) have results posted.
Among the 34 studies in Osteoporosis by Amgen, this one is the 18th largest by enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2006, is one of 5 in phase 2, and was the 5th registered.
Amgen’s Osteoporosis studies by the year they started, since 2002.
6 of the studies testing denosumab in Osteoporosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062978Phase 3Qilu Pharmaceutical Co., Ltd.A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | 2027-01 |
| NCT06332014AmgenEvaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China | 2027-01-23 |
| NCT04608630Australian and New Zealand Intensive Care Research CentreBone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults | 2027-02-28 |
| NCT04800367Columbia UniversityRomosozumab/Denosumab Study for Premenopausal IOP | 2027-03 |
| NCT07271771Aarhus University HospitalThe Effect of Denosumab on Muscle and Strength and Insulin Sensitivity | 2027-03-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies testing denosumab in Osteoporosis, from their registry updates:
Among Amgen’s 34 in Osteoporosis:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the effect of AMG 162 (denosumab) treatment on the lumbar spine BMD at month 12 and safety profile across the dose range tested (14, 60 and 100 mg SC once every 6 months) in Japanese postmenopausal osteoporotic subjects compared with those treated with placebo over 12 months.
Inclusion Criteria: - Ambulatory women. - BMD values (g/cm2, Hologic) must be lower than 0.714 at lumbar spine, 0.515 at femoral neck, 0.588 at total hip. - BMD values must not be lower than 0.535 at the lumbar spine, 0.406 at the femoral neck and 0.478 at the total hip. Exclusion Criteria: - Oral bisphosphonate treatments, PTH or PTH derivatives use within the last 12 months and administration of any of anti-osteoporotic treatments within the last 3 months before initial administration of the product. - History of hypocalcemia. - More than two moderate vertebral fractures or any severe vertebral fracture.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 100 mg AMG 162
Drug: 60 mg AMG 162
Drug: Placebo
Drug: 14 mg AMG 162
100 mg AMG 162 (denosumab) SC every 6 months
60 mg AMG 162 (denosumab) SC every 6 months
14 mg AMG 162 (denosumab) SC every 6 months
Placebo SC every 6 months
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 12 months
| Milestone | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Placebo |
|---|---|---|---|---|
| Started | 57 | 56 | 56 | 57 |
| Completed | 48 | 50 | 45 | 52 |
| Not completed | 9 | 6 | 11 | 5 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 3 | 3 | 2 | 2 |
| Withdrew: Withdrawal by subject | 4 | 2 | 8 | 1 |
| Withdrew: Ineligibility determined | 1 | 1 | 1 | 1 |
| Withdrew: Other | 1 | 0 | 0 | 0 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Placebo | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M |
|---|---|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 | .46 (-.23 to 1.15) | 5.71 (4.76 to 6.65) | 6.73 (5.71 to 7.75) | 7.45 (6.38 to 8.53) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 4/54 (7.4%) | 49/54 (90.7%) |
| Denosumab 14 mg Q6M | — | 6/53 (11.3%) | 50/53 (94.3%) |
| Denosumab 60 mg Q6M | — | 4/54 (7.4%) | 47/54 (87%) |
| Denosumab 100 mg Q6M | — | 2/51 (3.9%) | 48/51 (94.1%) |
| Event | Placebo | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M |
|---|---|---|---|---|
| HaemorrhoidsGastrointestinal disorders | 0/54 | 0/53 | 0/54 | 1/51 |
| Cerebral artery embolismNervous system disorders | 0/54 | 0/53 | 0/54 | 1/51 |
| Meniere's diseaseEar and labyrinth disorders | 0/54 | 1/53 | 0/54 | 0/51 |
| Colitis ischaemicGastrointestinal disorders | 0/54 | 1/53 | 0/54 | 0/51 |
| Colonic polypGastrointestinal disorders | 0/54 | 1/53 | 0/54 | 0/51 |
| Intestinal ischaemiaGastrointestinal disorders | 0/54 | 1/53 | 0/54 | 0/51 |
| Subdural haematomaInjury, poisoning and procedural complications | 0/54 | 1/53 | 0/54 | 0/51 |
| Varicose veinVascular disorders | 0/54 | 1/53 | 0/54 | 0/51 |
| PalpitationsCardiac disorders | 0/54 | 0/53 | 1/54 | 0/51 |
| ColitisGastrointestinal disorders | 1/54 | 0/53 | 0/54 | 0/51 |
| Event | Placebo | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 21/54 | 18/53 | 22/54 | 22/51 |
| Back painMusculoskeletal and connective tissue disorders | 4/54 | 3/53 | 8/54 | 9/51 |
| ContusionInjury, poisoning and procedural complications | 8/54 | 1/53 | 4/54 | 1/51 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 8/54 | 4/53 | 3/54 | 6/51 |
| HeadacheNervous system disorders | 5/54 | 7/53 | 6/54 | 3/51 |
| EczemaSkin and subcutaneous tissue disorders | 5/54 | 6/53 | 4/54 | 6/51 |
| PeriarthritisMusculoskeletal and connective tissue disorders | 6/54 | 1/53 | 1/54 | 1/51 |
| Joint sprainInjury, poisoning and procedural complications | 2/54 | 1/53 | 1/54 | 5/51 |
| HypoaesthesiaNervous system disorders | 3/54 | 1/53 | 2/54 | 5/51 |
| ConstipationGastrointestinal disorders | 1/54 | 5/53 | 5/54 | 2/51 |
| Age Continuous(Years) | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 65.9 ± 7.1 | 65.1 ± 6.3 | 64.6 ± 7.1 | 64.6 ± 7 | 65.1 ± 6.8 |
| Sex: Female, Male(Participants) | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Placebo | Total |
|---|---|---|---|---|---|
| Female | 53 | 54 | 50 | 55 | 212 |
| Male | 0 | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
The record gives a start of Jan 2006, a primary completion of Jun 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 2 years 7 months after primary completion. A results delay was requested in Nov 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab